Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Richard van Hillegersberg, Tom van den Ende, Sybren L. Meijer, Rob H.A. Verhoeven, Max Nieuwdorp, Mark P. G. Dings, Nadia Haj Mohammad, Tanja D. de Gruijl, Nicolien C. de Clercq, H.W.M. van Laarhoven, Jacques J. Bergman, Elisabeth D. Geijsen, Stella Mook, Sandor Schokker, Maarten C.C.M. Hulshof, Nicole C.T. van Grieken, Maarten F. Bijlsma, Bauke Ylstra, Jelle P. Ruurda, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Tanya T.D. Soeratram
Publikováno v:
van den Ende, T, Clercq, N D, van Berge Henegouwen, M I, Gisbertz, S S, Geijsen, D, Verhoeven, R, Meijer, S L, Schokker, S, Dings, M, Bergman, J J G H M, Haj Mohammad, N, Ruurda, J P, van Hillegersberg, R, Mook, S, Nieuwdorp, M, de Gruijl, T D, Soeratram, T T D, Ylstra, B, van Grieken, N C T, Bijlsma, M F, Hulshof, M C C M & van Laarhoven, H W 2021, ' Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma : A Single Arm Phase II Feasibility Trial (PERFECT) ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 12, pp. 3351-3359 . https://doi.org/10.1158/1078-0432.CCR-20-4443
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-
Autor:
Arjan W. Griffioen, Peter Timmerman, Ruben S. A. Goedegebuure, Hans J. van der Vliet, Tanja D. de Gruijl, Henk M.W. Verheul, Madelon Q. Wentink
Publikováno v:
Oncologist, 26, 2, pp. e218-e229
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Lessons Learned The novel therapeutic vaccine hVEGF26–104/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF26–104/RFASE failed to induce seroconversion against native hVEGF165 and, accordingly, neither a decrease in cir
Autor:
Iris de Weerdt, Tanja D. de Gruijl, Jurjen M Ruben, Hans van Vliet, Mark-David Levin, Lisa A King, Roeland Lameris, Arnon P. Kater, Paul W. H. I. Parren, Renate de Boer, Jan Kloosterman
Publikováno v:
de Weerdt, I, Lameris, R, Ruben, J M, de Boer, R, Kloosterman, J, King, L A, Levin, M-D, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 6, pp. 1744-1755 . https://doi.org/10.1158/1078-0432.CCR-20-4576
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Purpose: Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity tha
Autor:
Robbert S. Puijk, Rafael V. Davalos, Alette H. Ruarus, Martijn R. Meijerink, Hester J. Scheffer, Bart Geboers, Philip M. Graybill, Sanne Nieuwenhuizen, Petrousjka van den Tol, Boris Rubinsky, Tanja D. de Gruijl, Damijan Miklavčič
Publikováno v:
Geboers, B, Scheffer, H J, Graybill, P M, Ruarus, A H, Nieuwenhuizen, S, Puijk, R S, van den Tol, P M, Davalos, R V, Rubinsky, B, de Gruijl, T D, Miklavčič, D & Meijerink, M R 2020, ' High-Voltage Electrical Pulses in Oncology : Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy ', Radiology, vol. 295, no. 2, pp. 254-272 . https://doi.org/10.1148/radiol.2020192190
This review summarizes the use of high-voltage electrical pulses (HVEPs) in clinical oncology to treat solid tumors with irreversible electroporation (IRE) and electrochemotherapy (ECT). HVEPs increase the membrane permeability of cells, a phenomenon
Autor:
Arjan A. van de Loosdrecht, Tanja D. de Gruijl, Nathalie van Leeuwen-Kerkhoff, Theresia M. Westers, Pino J. Poddighe, Shahram Kordasti
Publikováno v:
Haematologica
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, de Gruijl, T D, Kordasti, S & van de Loosdrecht, A A 2020, ' Thrombomodulin expressing monocytes are associated with low risk features in myelodysplastic syndromes and dampen excessive immune activation ', Haematologica, vol. 105, no. 4, pp. 961-970 . https://doi.org/10.3324/haematol.2019.219303
Haematologica, 105(4), 961-970. Ferrata Storti Foundation
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, de Gruijl, T D, Kordasti, S & van de Loosdrecht, A A 2020, ' Thrombomodulin expressing monocytes are associated with low risk features in myelodysplastic syndromes and dampen excessive immune activation ', Haematologica, vol. 105, no. 4, pp. 961-970 . https://doi.org/10.3324/haematol.2019.219303
Haematologica, 105(4), 961-970. Ferrata Storti Foundation
The bone marrow of patients with low-risk myelodysplastic syndromes (MDS) is often an inflammatory environment and associated with an active cellular immune response. An active immune response generally contributes to antitumor responses and may prev
Publikováno v:
Cancer Immunology, Immunotherapy
Rotman, J, Koster, B D, Jordanova, E S, Heeren, A M & de Gruijl, T D 2019, ' Unlocking the therapeutic potential of primary tumor-draining lymph nodes ', Cancer Immunology, Immunotherapy, vol. 68, no. 10, pp. 1681-1688 . https://doi.org/10.1007/s00262-019-02330-y
Rotman, J, Koster, B D, Jordanova, E S, Heeren, A M & de Gruijl, T D 2019, ' Unlocking the therapeutic potential of primary tumor-draining lymph nodes ', Cancer Immunology, Immunotherapy, vol. 68, no. 10, pp. 1681-1688 . https://doi.org/10.1007/s00262-019-02330-y
Lymph nodes draining the primary tumor are essential for the initiation of an effective anti-tumor T-cell immune response. However, cancer-derived immune suppressive factors render the tumor-draining lymph nodes (TDLN) immune compromised, enabling tu
Autor:
Maartje Van Ruiten, Nienke E. van Trommel, Ekaterina S. Jordanova, John B. A. G. Haanen, Ton N. Schumacher, Gemma G. Kenter, Jossie Rotman, Marc van Beurden, Noor A. M. Bakker, Sanne Samuels, Bastiaan Nuijen, Karin E. de Visser, Tanja D. de Gruijl, Jos H. Beijnen, Henry Zijlmans, Joost H. van den Berg
Publikováno v:
Bakker, N A M, Rotman, J, Van Beurden, M, Zijlmans, H J M A A, Van Ruiten, M, Samuels, S, Nuijen, B, Beijnen, J, De Visser, K, Haanen, J, Schumacher, T, De Gruijl, T D, Jordanova, E S, Kenter, G G, Van Den Berg, J H & Van Trommel, N E 2021, ' HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN) : A phase I/II clinical trial ', Journal for Immunotherapy of Cancer, vol. 9, no. 8, 002547 . https://doi.org/10.1136/jitc-2021-002547
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
BackgroundUsual vulvar intraepithelial neoplasia (uVIN) is a premalignancy caused by persistent infection with high-risk types of human papillomavirus (HPV), mainly type 16. Even though different treatment modalities are available (eg, surgical excis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb52bf3c6adfbc91bc3923e54b6cf18
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
Autor:
Linde M. Veen, Tim L.P. Skrabanja, Hanneke W. M. van Laarhoven, Maarten F. Bijlsma, Tanja D. de Gruijl, Sarah Derks
Publikováno v:
Veen, L M, Skrabanja, T L P, Derks, S, de Gruijl, T D, Bijlsma, M F & van Laarhoven, H W M 2021, ' The role of transforming growth factor β in upper gastrointestinal cancers : A systematic review ', Cancer Treatment Reviews, vol. 100, 102285 . https://doi.org/10.1016/j.ctrv.2021.102285
Esophageal and gastric malignancies are associated with poor prognosis, in part due to development of recurrences or metastases after curative treatment. The transforming growth factor β (TGF-β) pathway might play a role in the development of treat
Publikováno v:
van Pul, K M, Fransen, M F, van de Ven, R & de Gruijl, T D 2021, ' Immunotherapy Goes Local : The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy ', Frontiers in Immunology, vol. 12, 643291, pp. 643291 . https://doi.org/10.3389/fimmu.2021.643291
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Immune checkpoint blockade (ICB) has changed the therapeutic landscape of oncology but its impact is limited by primary or secondary resistance. ICB resistance has been related to a lack of T cells infiltrating into the tumor. Strategies to overcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5daeb36ebe7bc070244de75184778a9
https://research.vumc.nl/en/publications/c1861d0d-26a3-4232-aaf8-661efa5296a2
https://research.vumc.nl/en/publications/c1861d0d-26a3-4232-aaf8-661efa5296a2
Autor:
Jeffrey E. Gershenwald, Michael T. Tetzlaff, Peter A. Prieto, Jennifer L. McQuade, Charlotte E. Ariyan, Jonathan S. Zager, David F. McDermott, Adil Daud, Christian U. Blank, Kim Margolin, Richard A. Scolyer, Brett W. Carter, Elizabeth M. Burton, Richard D. Carvajal, Jeffrey A. Sosman, Alexander N. Shoushtari, April K.S. Salama, Scott E. Woodman, Tina J. Hieken, Vernon K. Sondak, Douglas S. Tyler, Jeffrey E. Lee, Frances C. Wright, Omid Hamid, David E. Fisher, Tanja D. de Gruijl, Miles C. Andrews, Michael C. Lowe, John M. Kirkwood, Keith T. Flaherty, Mark B. Faries, Grant A. McArthur, Dirk Schadendorf, Alexander C.J. van Akkooi, Alberto Fusi, Bart A. van de Wiel, James Larkin, Ken K. Tanabe, Jane L. Messina, Jennifer A. Wargo, Rodabe N. Amaria, Jonathan Cohen, Shaneen Sandhu, Andrew J. Spillane, Reinhard Dummer, Robert Antdbacka, Michael A. Postow, Michael D. Farwell, Céleste Lebbé, Jason J. Luke, Genevieve M. Boland, Tara C. Mitchell, David H. Lawson, Elisa A. Rozeman, Diwakar Davar, Caroline Robert, Kathryn Bollin, Ryan J. Sullivan, Michael A. Davies, Matteo S. Carlino, Isabella C. Glitza, Robyn P. M. Saw, Merrick I. Ross, Axel Hauschild, Teresa M. Petrella, Paolo A. Ascierto, Serigne Lo, Igor Puzanov, Samra Turajlic, Angela Hong, Roland L. Bassett, Keith A. Delman, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Susan M. Swetter, Janis M. Taube, Alexander M.M. Eggermont, John F. Thompson, Donald A. Berry, Leslie A. Fecher, Matthew S. Block, Alexander M. Menzies, David E. Gyorki, Helen Rizos
Publikováno v:
The Lancet Oncology. 20:e378-e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of